Core Viewpoint - A class action securities lawsuit has been filed against ESSA Pharma Inc. due to alleged securities fraud affecting investors between December 12, 2023, and October 31, 2024 [1][2]. Group 1: Allegations and Claims - The lawsuit claims that the defendants made false statements regarding the efficacy of masofaniten in combination with enzalutamide, suggesting it had no clear benefit over enzalutamide alone [2]. - It is alleged that masofaniten was less effective in treating prostate cancer than previously communicated to investors [2]. - The M-E Combination Study, which was intended to evaluate the treatment's effectiveness, is said to be unlikely to meet its Phase 2 primary endpoint as previously stated [2]. - The defendants are accused of overstating masofaniten's clinical, regulatory, and commercial prospects, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until March 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

NEW YORK, Feb. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") (NASDAQ: EPIX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of ESSA Pharma Inc. investors who were adversely affected by alleged securities fraud between December 12, 2023 and October 31, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/essa-pharma- ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ESSA Pharma To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Feb. 20, 2025 / ...

NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ESSA Pharma Inc. (NASDAQ: EPIX) between December 12, 2023 and October 31, 2024, inclusive (the “Class Period”), of the important March 25, 2025 lead plaintiff deadline. SO WHAT: If you purchased ESSA Pharma Inc. securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WH ...

NEW YORK, Feb. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") (NASDAQ: EPIX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of ESSA Pharma Inc. investors who were adversely affected by alleged securities fraud between December 12, 2023 and October 31, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/essa-pharma- ...

Company continues to explore and review strategic options focused on maximizing shareholder valueSOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 11, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal first quarter ended December ...

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") (NASDAQ: EPIX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of ESSA Pharma Inc. investors who were adversely affected by alleged securities fraud between December 12, 2023 and October 31, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/essa-pharma- ...

Financial Position - Total assets increased by $8.4 million, or 0.4%, to $2.2 billion at December 31, 2024, primarily due to increases in cash and loans receivable[115]. - Total cash and cash equivalents rose by $4.4 million, or 9.0%, to $52.9 million at December 31, 2024[116]. - Net loans increased by $11.9 million, or 0.7%, to $1.76 billion at December 31, 2024, with residential loans up by $9.4 million to $731.0 million[116][117]. - Deposits increased by $70.9 million, or 4.4%, to $1.70 billion at December 31, 2024, driven by a rise in certificates of deposit and money market accounts[121]. - Stockholders' equity increased by $3.8 million, or 1.6%, to $234.2 million at December 31, 2024, primarily due to net income of $4.0 million[123]. Income and Expenses - Net income decreased by $381,000, or 8.8%, to $4.0 million for the three months ended December 31, 2024, compared to the same period in 2023[127]. - Net interest income decreased by $720,000, or 4.8%, to $14.1 million for the three months ended December 31, 2024[128]. - Total interest income was $26.4 million for the three months ended December 31, 2024, reflecting an increase in the yield on average interest-earning assets to 5.01%[129]. - Noninterest income increased by 5.0% to $2.1 million for the three months ended December 31, 2024, compared to the same period in 2023[132]. - Noninterest expense increased by $77,000, or 0.7%, to $11.9 million for the three months ended December 31, 2024, primarily due to higher compensation and employee benefits[133]. Asset Quality - Total non-performing assets decreased by $432,000 from September 30, 2024, to December 31, 2024, totaling $11.789 million[137]. - The ratio of non-performing loans to total loans was 0.49% as of December 31, 2024, down from 0.51% on September 30, 2024[137]. - The allowance for credit losses to total loans ratio was 0.85% as of December 31, 2024[137]. Cash Flow - Net cash provided by operating activities was $3.1 million for the three months ended December 31, 2024, compared to $6.7 million for the same period in 2023[143]. - Net cash used for investing activities was $(6.7) million for the three months ended December 31, 2024[143]. Borrowings and Commitments - Outstanding borrowings from the Pittsburgh FHLB were $225.0 million, with total access to FHLB advances of approximately $872.7 million[140]. - Loan commitments outstanding totaled $380.3 million, including $93.2 million in undisbursed construction loans[142]. Risk Management - The company has no off-balance sheet arrangements that could materially affect its financial condition[151]. - The company has maintained its interest rate risk management strategy without material changes since September 30, 2024[153].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ESSA Pharma To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Feb. 7, 2025 /P ...

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) and certain officers. The class action, filed in the United States District Court for the Eastern District of Wisconsin, and docketed under 25-cv-00124, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired ESSA securities between December 12, 2023 and October 31, 2024, b ...